Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan‐Induced DNA Double‐Strand Breaks in Uveal Melanoma
Pigment Cell & Melanoma Research · 2026-07 · 39 (4)
DOI: 10.1111/pcmr.70104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 19.06.2026. Verfasst von Iuliia Pavlyk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-A Cancer Research UK Center of Excellence, John Vane Science Center, Q…. Hauptthemen laut MEDLINE: Melanoma, Melphalan, Uveal Neoplasms, Polyethylene Glycols. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polaris Pharmaceuticals.
Abstract (Originalsprache)
Uveal melanoma is a hard‐to‐treat arginine‐dependent cancer secondary to argininosuccinate synthetase 1 (ASS1) loss with half of patients succumbing to liver‐dominant metastases. Arginine deprivation with pegargiminase is a novel antimetabolite strategy for patients with uveal melanoma. We investigated the preclinical rationale for combining pegargiminase with melphalan, an alkylating agent approved recently for the treatment of hepatic‐centric disease. Drug sensitivity of ASS1‐deficient uveal melanoma cell lines was performed in 2D culture using proliferation and cytotoxicity assays, with analysis of cell death, cell cycle, DNA double‐strand breaks, and interrogation of the molecular mechanism of action by RNA‐seq. ADI‐PEG20 and melphalan suppressed uveal melanoma cell line proliferation and triggered cytotoxicity, effects which were enhanced with the drug combination. ADI‐PEG20 downregulated multiple genes of the Fanconi anemia pathway and synergized with melphalan to increase DNA double‐strand breaks. Melphalan and pegargiminase is a rational new drug combination that warrants clinical testing in uveal melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-A Cancer Research UK Center of Excellence, John Vane Science Center, Queen Mary University of London, London, UK.
- University of East Anglia, Norwich, UK.
- The London Clinic, London, UK.
- Department of Brain Sciences, Hammersmith Hospital, Imperial College London, London, UK.
- Polaris Pharmaceuticals Inc., San Diego, California, USA.
- Wellcome Sanger Institute, Hinxton, UK.
ORCID-Profile: Matthew Young, Pui Ying Chan, Peter W Szlosarek
Förderung
- Polaris Pharmaceuticals
Zitieren
APA
Pavlyk, I., Field, G., Young, M., Carpentier, J., Szlosarek, E. A., O'Keeffe-Brown, M. R., Crook, T., Syed, N., Bomalaski, J. S., Chan, P. Y., & Szlosarek, P. W. (2026). Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan‐Induced DNA Double‐Strand Breaks in Uveal Melanoma. Pigment Cell & Melanoma Research, 39(4). https://doi.org/10.1111/pcmr.70104
Vancouver
Pavlyk I, Field G, Young M, Carpentier J, Szlosarek EA, O'Keeffe-Brown MR, et al. Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan‐Induced DNA Double‐Strand Breaks in Uveal Melanoma. Pigment Cell & Melanoma Research. 2026;39(4). doi:10.1111/pcmr.70104
BibTeX
@article{Pavlyk2026,
author = {Pavlyk, Iuliia and Field, George and Young, Matthew and Carpentier, Josephine and Szlosarek, Emilia A and O'Keeffe-Brown, Michaela R and Crook, Timothy and Syed, Nelofer and Bomalaski, John S and Chan, Pui Ying and Szlosarek, Peter W},
title = {Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan‐Induced DNA Double‐Strand Breaks in Uveal Melanoma},
journal = {Pigment Cell & Melanoma Research},
year = {2026},
volume = {39},
number = {4},
doi = {10.1111/pcmr.70104}
}
EUVIMED